Mirikizumab: Primary completion of P3 LUCENT 1 trial (NCT03518086) in moderate-to-severe ulcerative colitis in Sep 2020 (Eli Lilly) - Apr 23, 2020 - Q1 2020 Results: Completion of P3 LUCENT 1 trial in moderate-to-severe ulcerative colitis in Dec 2021
Trial completion date • Trial primary completion date • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
|